AlphaQuest LLC Buys New Position in Becton, Dickinson and Company $BDX

AlphaQuest LLC purchased a new position in Becton, Dickinson and Company (NYSE:BDX) in the third quarter, Holdings Channel.com reports. The fund purchased 4,991 shares of the medical instruments supplier’s stock, valued at approximately $934,000.

Other institutional investors also recently bought and sold shares of the company. SOA Wealth Advisors LLC. increased its stake in shares of Becton, Dickinson and Company by 256.8% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 95 shares in the last quarter. Activest Wealth Management boosted its stake in Becton, Dickinson and Company by 285.3% in the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 97 shares in the last quarter. Bell Investment Advisors Inc increased its stake in Becton, Dickinson and Company by 474.1% during the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 128 shares in the last quarter. Grey Fox Wealth Advisors LLC purchased a new position in Becton, Dickinson and Company in the third quarter worth about $32,000. Finally, Bank of Jackson Hole Trust lifted its stake in shares of Becton, Dickinson and Company by 85.6% in the second quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock worth $35,000 after buying an additional 95 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on BDX. Stifel Nicolaus boosted their price target on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Jefferies Financial Group raised their target price on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Bank of America increased their price target on Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a report on Monday, January 5th. Finally, Wall Street Zen cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Four analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and an average price target of $209.00.

Insider Transactions at Becton, Dickinson and Company

In other news, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the transaction, the director directly owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. This trade represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 2,680 shares of company stock worth $539,848. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of NYSE:BDX opened at $202.29 on Tuesday. The firm has a fifty day simple moving average of $198.76 and a two-hundred day simple moving average of $191.57. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $251.99. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $57.63 billion, a P/E ratio of 34.70, a PEG ratio of 2.25 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share for the quarter, beating the consensus estimate of $3.92 by $0.04. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The firm had revenue of $5.89 billion for the quarter, compared to the consensus estimate of $5.91 billion. During the same quarter in the previous year, the company posted $3.81 EPS. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. On average, analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be paid a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s payout ratio is currently 72.04%.

Becton, Dickinson and Company announced that its Board of Directors has authorized a stock repurchase program on Tuesday, January 27th that allows the company to repurchase $10.00 million in shares. This repurchase authorization allows the medical instruments supplier to reacquire up to 0% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.